Brian J. Capaldo, Ph.D.
- Center for Cancer Research
- National Cancer Institute
- Building 37, Room 1066A
- Bethesda, MD 20892
- 240-760-6606
- capaldobj@nih.gov
RESEARCH SUMMARY
Dr. Capaldo's research focuses on identifying best practices in bioinformatics and computational biology and applying these to biological problems to generate testable hypotheses in the field of prostate cancer.
Areas of Expertise
1) bioinformatics 2) RNA sequencing 3) single cell 4) computational epigenomics 5) computational high parameter cytometry
Brian J. Capaldo, Ph.D.
Research
My research interests are focused on the integrative statistical analysis of high-throughput molecular assays, specifically sequencing data and high-dimensional single cell data. Much of my work has been devoted to the analysis and interpretation of the transcriptomic response to perturbation of signaling through the use of single- and combination-targeted therapies in prostate cancer, as well as identifying molecular phenotypes of adenocarcinoma, neuroendocrine prostate cancer, and mechanisms of castrate-resistant prostate cancer.
Publications
Responses to MAP Kinase Pathway Blockade in BRAF Mutant Melanoma
An integrated framework using high-dimensional mass cytometry and fluorescent flow cytometry identifies discrete B cell subsets in patients with red meat allergy
Biography
Brian J. Capaldo, Ph.D.
Brian J. Capaldo received his B.S. in molecular and cellular biology from Johns Hopkins University, where he undertook part of the Synthetic Yeast Genome Project under Dr. Jef Boeke. He went on to the University of Virginia (UVA) to obtain a Ph.D. in the lab of Stefan Bekiranov, where he studied computational biology focusing on identifying mechanisms of sensitivity and resistance to single and combinatorial therapy in melanoma and B cell malignancies. After his defense, he joined the UVA School of Medicine Core Facilities, supporting the Mass Spectrometry, Flow Cytometry, and Bioinformatics Cores.
Dr. Capaldo was drawn to the Laboratory of Genitourinary Cancer Pathogenesis to continue his work in molecular phenotyping and identification of mechanisms of resistance to targeted therapy in cancer. He joined in April of 2018 as a Bioinformatics Scientist.